5 Key Takeaways

• 1

  ELAAVATE is an investigator-initiated phase 2 study evaluating the safety and efficacy of subretinal sura-vec in center-involving diabetic macular edema.

• 2

  After 9 surgeries in phakic and pseudophakic patients, investigators reported no new safety signals or surgical complications.

• 3

  Retinal pigmentary changes occurred later and were less intense than those observed in patients with neovascular age-related macular degeneration.

• 4

  Investigators reported dose-dependent responses, and most patients received 0 or 1 supplemental injection while maintaining disease control.

• 5

  Patients received a topical steroid taper, and no oral or long-term topical immunosuppression was used.